Macquarie Group LTD Altimmune, Inc. Transaction History
Macquarie Group LTD
- $87.4 Billion
- Q1 2024
A detailed history of Macquarie Group LTD transactions in Altimmune, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 44,474 shares of ALT stock, worth $295,752. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,474Holding current value
$295,752% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ALT
# of Institutions
185Shares Held
44.4MCall Options Held
1.1MPut Options Held
647K-
State Street Corp Boston, MA8.65MShares$57.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.04MShares$26.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.13MShares$20.8 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$18.3 Million3.41% of portfolio
-
Morgan Stanley New York, NY2.21MShares$14.7 Million0.0% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $326M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...